Zolmitriptan inhalation (Acorda Therapeutics)

N/A

Report date: 2024/04/12 20:03:58

Base Information

Drug NameZolmitriptan inhalation (Acorda Therapeutics)
Drug Alias NameZolmitriptan Inhalation Powder (Acorda Therapeutics)CVT-427
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1a (5-HT1a) receptor agonistsSerotonin 1b (5-HT1b) receptor agonistsSerotonin 1d (5-HT1d) receptor agonists
TargetsSerotonin 1a (5-HT1a) receptorSerotonin 1b (5-HT1b) receptorSerotonin 1d (5-HT1d) receptor
Therapy Area/IndicationsMigraine Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCivitas Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesAcorda Therapeutics
Active IndicationsN/A
Inactive IndicationsMigraine Disorders

Other Information

ATC CodeN/A
Related LinksN/A